23.43
-0.97(-3.98%)
Currency In USD
| Previous Close | NaN |
| Open | NaN |
| Day High | NaN |
| Day Low | NaN |
| 52-Week High | NaN |
| 52-Week Low | NaN |
| Volume | NaN |
| Average Volume | NaN |
| Market Cap | NaN |
| PE | NaN |
| EPS | NaN |
| Moving Average 50 Days | NaN |
| Moving Average 200 Days | NaN |
| Change | NaN |
If you invested $1000 in uniQure N.V. (QURE) 10 years ago, it would be worth $1,511.61 as of February 21, 2026 at a share price of $23.43. Whereas If you bought $1000 worth of uniQure N.V. (QURE) shares 5 years ago, it would be worth $645.45 as of February 21, 2026 at a share price of $23.43.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Data not available
uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease
GlobeNewswire Inc.
Feb 06, 2026 12:05 PM GMT
~ Supraphysiological expression of α-Gal A activity maintained for over a year in longest treated patient as of data cutoff date ~ ~ Stable Lyso-Gb3 levels maintained post-dosing, regardless of enzyme replacement therapy status across all cohorts ~ ~
uniQure Announces Type A Meeting Scheduled with FDA
GlobeNewswire Inc.
Jan 09, 2026 12:05 PM GMT
LEXINGTON, Mass. and AMSTERDAM, Jan. 09, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced a Type A meeting with the U.S.
uniQure to Announce Third Quarter 2025 Financial Results
GlobeNewswire Inc.
Nov 06, 2025 12:05 PM GMT
~ uniQure to host earnings call on Monday, November 10, 2025 at 8:30 a.m. ET ~LEXINGTON, Mass. and AMSTERDAM, Nov. 06, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patie